Results of a European survey into stem cell transplants for patients with myelofibrosis (MF) showed significantly varying approaches to their management in this era of JAK inhibitors. The lead researcher on the study stated that the field of MF is changing rapidly and the decision on the timing of allo-HCT will become even harder.
The survey focused on real world experience at 19 different centres and findings “highlight significant heterogeneity in practice, which is likely to increase as more novel agents are integrated in treatment algorithms. Harmonised, multidisciplinary guidelines to optimise timing and outcomes for MF patients eligible for allo-HCT are needed.”
The article has the catchy title ‘A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on ‘real world’ experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm’.
The full article is free to access and is available HERE.
